Literature DB >> 17105517

Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation.

Roger Kurlan1, Irene Hegeman Richard, Cheryl Deeley.   

Abstract

Restless legs syndrome (RLS) is a common condition characterized by an unpleasant urge to move the legs that usually occurs at night and may interfere with sleep. The medications used most commonly to treat RLS include dopaminergic drugs (levodopa, dopamine agonists), benzodiazepines, and narcotic analgesics. We report the cases of 2 patients with RLS who illustrate the problems of tolerance (declining response over time) and augmentation (a worsening of symptoms due to ongoing treatment) that can complicate the pharmacotherapy of RLS. We discuss the optimal management of RLS and propose strategies to overcome tolerance and augmentation such as a rotational approach among agents from different classes.

Entities:  

Mesh:

Year:  2006        PMID: 17105517      PMCID: PMC1924754          DOI: 10.1111/j.1525-1497.2006.00593.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  20 in total

Review 1.  Restless legs syndrome: treatment with dopaminergic agents.

Authors:  Cynthia L Comella
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

Review 2.  Clinical practice. Restless legs syndrome.

Authors:  Christopher J Earley
Journal:  N Engl J Med       Date:  2003-05-22       Impact factor: 91.245

3.  Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.

Authors:  Richard K Bogan; June M Fry; Markus H Schmidt; Stanley W Carson; Sally Y Ritchie
Journal:  Mayo Clin Proc       Date:  2006-01       Impact factor: 7.616

4.  Restless legs syndrome.

Authors:  C Clough
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

5.  Dopaminergic treatment of restless legs and rebound phenomenon.

Authors:  C Guilleminault; M Cetel; P Philip
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

6.  Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.

Authors:  D Garcia-Borreguero; O Larrosa; Y de la Llave; K Verger; X Masramon; G Hernandez
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

7.  Restless legs syndrome and its treatment by dopamine agonists.

Authors: 
Journal:  Parkinsonism Relat Disord       Date:  2000-11-01       Impact factor: 4.891

8.  An algorithm for the management of restless legs syndrome.

Authors:  Michael H Silber; Bruce L Ehrenberg; Richard P Allen; Mark J Buchfuhrer; Christopher J Earley; Wayne A Hening; David B Rye
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

9.  Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.

Authors:  Arthur S Walters; William G Ondo; Tilman Dreykluft; Ron Grunstein; Daniel Lee; Kapil Sethi
Journal:  Mov Disord       Date:  2004-12       Impact factor: 10.338

10.  Iron status and restless legs syndrome in the elderly.

Authors:  S T O'Keeffe; K Gavin; J N Lavan
Journal:  Age Ageing       Date:  1994-05       Impact factor: 10.668

View more
  3 in total

1.  Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.

Authors:  Allan Wang; Keyana Foster; Patrick Skeba; Kasidet Hiranniramol; Christopher J Earley; Richard P Allen
Journal:  Sleep Med       Date:  2018-08-17       Impact factor: 3.492

2.  Augmentation in Restless Legs Syndrome: Treatment with Gradual Medication Modification.

Authors:  Adam Rosenstein; Marcie Rabin; Roger Kurlan
Journal:  Open Neurol J       Date:  2015-05-29

3.  Peripheral Dopamine in Restless Legs Syndrome.

Authors:  Ulrike H Mitchell; J Daniel Obray; Erik Hunsaker; Brandon T Garcia; Travis J Clarke; Sandra Hope; Scott C Steffensen
Journal:  Front Neurol       Date:  2018-03-15       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.